정부출연연구기관 지적재산권 활용현황과 과제

최치호,Choe, Chi-Ho 과학기술정책연구원 2002 과학기술정책 Vol.- No.138

과민대장증후군 환자를 소시호탕 합 작약감초탕 및 침 치료로 호전시킨 1례 : 증례보고

최치호,권승원,Choi, Chiho,Kwon, Seungwon 대한한방내과학회 2022 大韓韓方內科學會誌 Vol.43 No.5

Objectives: Irritable bowel syndrome is a functional disorder of the gastrointestinal tract marked by chronic abdominal pain and altered bowel habits. Irritable bowel syndrome is experienced by 11% of the global population. Although antidepressants and antispasmodic agents are currently used as therapeutic methods, they have side effects, so safer treatment agents are needed. Hence, I report the case of an outpatient who suffers from irritable bowel syndrome. Methods: The patient visited a public health center 14 times over four weeks and was treated with acupuncture and herbal medicine (Sosiho-tang and Jakyakgamcho-tang). Treatment progress was assessed using the Irritable Bowel Syndrome Severity Scoring System. Results: After 28 days of treatment, the Irritable Bowel Syndrome Severity Scoring System score decreased from 410 to 30 points without adverse events. The patient was highly satisfied. Conclusion: Sosiho-tang and Jakyakgamcho-tang with acupuncture might become recommended therapeutic options for irritable bowel syndrome patients.

병렬 RISC시스템상에서의 효율적인 데이터 저장기법 ( An Efficient Data Storage Scheme for Parallel RISC Systems )

최치호,고우종,김영우,허용민,김성중,이상정,임인칠 대한전자공학회 1992 대한전자공학회 학술대회 Vol.1992 No.11

개방형 혁신체제에서 기술보호 및 확보방안에 대한 법제도적 고찰

최치호 한국산업보안연구학회 2009 한국산업보안연구 Vol.1 No.1

개방형 혁신 환경 속에서 미래신성장 동력을 찾으려는 기업과 이미 보유하고 있는 기업에게는 두가지 도전적인 과제를 던져 준다. 즉, 보유 핵심기술을 어떻게 보호할 것인가와 외부로부터 신성장 동력기술 을 제대로 확보할 것 인가이며, 전자는 인력 유동성의 증가와 맞물려, 후자는 국가별 특허법제도나 기술 이전 규제상의 차이와 맞물려 복잡한 문제를 안고 있다. 본고에서는 이러한 기술보호 및 기술확보와 관 련하여 유의해야 할 사항을 법제도적 관점에서 집중적으로 고찰하였다. 우선, 기술보호를 위한 구체방안으로 연구협의단계에서 자사의 영업비밀을 적정하게 관리하기 위한 조직적 관리와 타사의 영업비밀을 침해하지 않기 위한 조직적 관리의 이원적 관리체제를 기반으로 영업 비밀 관리체제 정비방안, 제3자의 영업비밀에 대한 보호조치, 종업원․퇴직자에 대한 비밀관리대책 및 비 밀유지계약 등 법적 조치를 검토하였다. 연구수행 중의 보호조치로서 연구기록 유지관리체제 구축과 계 약이행을 위한 법무 관리체제 구축 등을 제안하였다. 특히 협력상대방이 경쟁기업에 인수합병되어 영업 비밀이 유출되거나 개발기술을 소유하거나 이전기술을 실시할 수 있는 사태를 방지하기 위한 방안 등을 포함하여 실무에 적용할 수 있는 현실적인 대비책을 제시하였다. 기술확보를 위한 구체 방안으로 발명자 인정기준, 특허권 공유, 국내우선출원의무 등의 법제 차이에 따라 연구성과인 특허권을 확보하지 못하는 문제점과 이에 대한 대처방안을 검토하였으며, 이러한 문제 점을 해소하기 위한 최근 해외법제의 동향을 살펴보면서 개방형 혁신을 촉진하기 위한 입법조치를 제언 하였다.

血淸 Digoxin 有效治療濃度에 關한 硏究

崔致浩,徐舜圭 고려대학교 의과대학 1985 고려대 의대 잡지 Vol.22 No.3

The serum therapeutic level of digoxin is widely variable and the determination of digitalization and maintenance doses is more or less empirical. Author intended to study the range of therapeutic level of digoxin and its relation to the doses of digoxin as well as factors controlling the serum level of digoxin. The subjects to study were 65 cases including 6 normal adults and 59 cases of heart diseases with congestive heart failure. 33 cases were male and 32 cases were female with mean age of 56.2 years and serum digoxin levels were measured 83 times by radioimmunoassay method. Normal 6 adults were given daily 0.75mg of digoxin for 3 days and followed by daily 0.25mg of digoxin for 3 days. The serum digoxin levels were measured on next morning of each last medication of digitalization and maintenance. The serum digoxin level of 9 patients with heart failure who were not responded to digoxin were measured more than twice. The serum digoxin levels were also measured in 40 patients with heart failure with serum creatinine less than 2mg% and with good response to digoxin and in 9 patients with heart failure and with serum creatinine more than 2mg%. The correlation between serum digoxin levels and factors such as body weight, height, cardiothoracic ratio, R in V_(E). serum calcium, potassium, total serum protein and albumin were also examined. Following results were obtained; 1. In 6 normal adults, the mean serum digoxin level was 1.44±0.574(ranging 0.72-2.25) ng/ml after daily digoxin 0.75mg for 3 days and was 0.89±0.454(ranging 0.49-1.50) ng/ml after daily digoxin 0.25mg for 3days. These data showed that the serum digoxin level varied depending on doses of medication and also there was considerable individual variation of serum digoxin level with same doses of digoxin. 2. In 9 patients with heart failure and refractory response to digoxin, the serum digoxin increased by continuing medication. 3. In 40 patients with serum creatinine less than 2mg% and heart failure with good the rapeutic response to digoxin, the mean serum digoxin level was 1.05±0.461 ng/ml ranging 0.25-2.18ng/ml and the serum therapeutic digoxin level of most patients was in range of 0.5-2.0ng/ml. 4. In 10 patients with serum creatinine more than 2mg% and heart failure, various doses of digoxin mere given and the mean serum digoxin level was 2.40±1.276ng/ml. There were cases of which serum digoxin were 3.20 and 4.21ng/ml with daily digoxin only 0.125mg respectively. These data showed that the digoxin was accumulated in patients with deterionated renal function. 5. There appeared to be same mild negative correlation between body weight and serum digoxin and positive correlation between cardio-thoracic ratio, serum calcium, and serum digoxin.

개방형 혁신하에서 혁신촉진을 위한 지식재산정책 및 법제도에 대한 소고

최치호 과학기술정책연구원 2010 과학기술정책 Vol.- No.181

정부출연연구기관의 지적재산권활용현황과 과제

최치호 과학기술정책연구원 2002 과학기술정책 Vol.- No.138

스마트폰 사용 시 실내조명환경과 눈의 피로도와의 상관관계 분석

최치호(Chi-Ho Choi),김인태(In-Tae Kim),최안섭(An-Seop Choi) 한국조명·전기설비학회 2015 한국조명·전기설비학회 학술대회논문집 Vol.2015 No.5

홈 네트워크에서 센서를 장착한 PDA를 기반으로 한 상황 인식 프레임워크

최치호(Chi-ho Choi),이승륜(Seung-ryun Lee),박준호(Jun-ho Park),이명진(Myung-jin Lee),강순주(Soon-ju Kang) 한국정보과학회 2004 한국정보과학회 학술발표논문집 Vol.31 No.2Ⅱ

일반적으로 상황 인식 서비스를 제공하기 위해서는 가전 제품이나 건물에 센서를 장착하여 사용자의 위치를 파악하고 이에 알맞은 상황 인식 서비스를 제공한다. 그러나 이러한 경우에는 많은 수의 센서를 설치해야 함으로 설치 및 유지보수 비용과 전역소모가 않았다. 본 논문에서는 이러한 단점을 보완하기 위하여 단지 3가지 센서(자이로 센서, 컴퍼스 센서, 초음파 센서)만을 장착한 PDA(Person Digital Assistants)를 이용한 홈 네트워크에서의 상황 인식 서비스를 제안한다. 센서를 장착한 PDA를 이용하여 사용자는 제어하거나 상태 정보를 원하는 가전 제품을 가리키게 되고 센서 데이터 값을 이용하여 사용자에게 유용한 상황 인식 서비스를 제공할 수 있는 방법을 제시한다.

특허권실시계약에서 실시권자의 부쟁(不爭)의무에 대한 법적 고찰

최치호 ( Chi-ho Choi ) 한국지식재산연구원 2008 지식재산연구 Vol.3 No.1

This study examines the possibility of a licensee claiming invalidity of certain licensed patents in the Prinzip von Treu und Glauben (principle of trust and faith) and estoppel perspective, based on legal grounds of doctrines and judicial precedents. The results show that invalidation trials not only simply arbitrate private persons's interests, but also function as a process to nullify the right to a monopoly of certain technology that should not have been given the right in the first place, the process thus fulfilling public interests. Therefore, considering that enlarging the appropriateness scope of applicants as large as possible suits the purpose, it would be reasonable to contradict the non-contestability duty in principle and recognize the non-contestability duty only in very exceptional situations. Such exceptional situations may include where a special relationship is recognized with interested parties concluding a licensing agreement through bilateral reconciliation and simultaneously agreeing to withdraw trial requests, and yet the case is subject to considerable violation of the principle of trust and faith. Next, since the legal validity of imposing the non-contestability duty on licensees has been much discussed in many countries including the matter of violation of the Antimonopoly Act, legal force of the Antimonopoly Act regarding the non-contestability duty in the United States, Japan, Korea and Europe is surveyed. Also, the U.S. judicial precedents, which have greatly influenced revisions of Antimonopoly Acts in other countries, are examined. The results show that although non-contestability agreement is basically valid in the principle of private autonomy perspective, such validity of the agreement is denied accordingly when it violates good public order and customs or the Antimonopoly Act. That is, because there may be another interested party besides the licensee, the corresponding right may be attacked by a third party even if the licensee's request for an invalidation trial is hindered. Thus, the non-contestability duty clause does not directly harm public interests. Also, the non-contestability duty clause may help amicably conclude a licensing agreement, thus facilitating use of rights. Therefore, the non-contestability duty should not necessarily be invalidated.